Its compounded semaglutide product was never the be-all and end-all for Hims & Hers ... This means that FDA does not review these drugs to evaluate their safety, effectiveness, or quality before ...

Hims saw massive revenue growth in 2024 as it sold compounded versions of Novo Nordisk’s semaglutide. This is the clinical name for Novo’s Wegovy and Ozempic. The FDA allowed this because ...

It has expanded its offerings to include weight loss, focusing on prescription medications, including its own compounded semaglutide ... But some recent Hims and Hers reviews complain about ...

Shares of the health and wellness platform operator skyrocketed more than 670% between Jan. 1, 2024, and Feb. 19, 2025. However, this sizzling momentum came to a screeching halt in recent weeks. Hims ...

The company says its semaglutide injections are fulfilled and shipped from Hims & Hers' affiliated pharmacies ... legal and regulatory (MLR) reviews. In a new pharmaphorum podcast, web editor ...

Many treatments are available, and with the popularity of online and mail-order services in recent years, two leaders are BlueChew and Hims. Both companies offer different ED treatments and a ...

Hims & Hers had previously offered compounded versions of semaglutide -- the GLP-1 drug marketed as Ozempic and Wegovy -- which it and other compounding pharmacies were allowed to do legally ...

Learn More » Much of the excitement over Hims & Hers has been connected to the company's sales of compounded versions of GLP-1 inhibitor semaglutide. Novo Nordisk markets semaglutide as a ...